- Home
- DBL vs CADL Comparison
DBL vs CADL Comparison
Compare DBL & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DBL | CADL |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.3M | 320.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DBL | CADL |
|---|---|---|
| Price | $15.16 | $5.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | 61.0K | ★ 738.2K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.75 | $4.25 |
| 52 Week High | $15.70 | $13.68 |
Technical Indicators
Market Signals| Indicator | DBL | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 42.62 |
| Support Level | $15.01 | $5.24 |
| Resistance Level | $15.30 | $6.11 |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 65.52 | 13.04 |
Price Performance
Historical ComparisonAbout DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.